What question did this study set out to answer?

This research aims to clarify the issues related to the FDA's Inactive Ingredient Database and its implications for generic drug formulation.

April 11, 2026

Recent confusion and ongoing actions related to the FDA’s Inactive Ingredient Database (IID) - What should be included in the ANDA?

View Full Paper

Ask AI

Bookmark

Authors

Reports confusion about excipient limits in generic drugs, suggesting improvements to the IID for clearer guidelines.

This research aims to clarify the issues related to the FDA's Inactive Ingredient Database and its implications for generic drug formulation.
Analysis of the current structure of the Inactive Ingredient Database
Examination of excipient selection practices among generic drug manufacturers
Evaluation of the impact of unclear regulations on drug formulation
Generic manufacturers are selecting excipient amounts based on safety rather than effectiveness.
The current IID lacks clear guidelines, leading to confusion in formulation decisions.
Recommendations for modernizing the IID to improve formulation clarity and enhance drug safety.

David R Schoneker (2016) studied this question.

View Full Paper

Ask AI

Bookmark